DrugPatentWatch Database Preview

Details for Patent: 9,050,302

« Back to Dashboard

Which drugs does patent 9,050,302 protect, and when does it expire?

Patent 9,050,302 protects XYREM and is included in one NDA.

Protection for XYREM has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-one patent family members in eighteen countries.

Summary for Patent: 9,050,302

Title:	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Abstract:	One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
Inventor(s):	Eller; Mark (Redwood City, CA)
Assignee:	Jazz Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:	13/837,714
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,050,302
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,050,302

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y

International Family Members for US Patent 9,050,302

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014223373
Brazil	112015021012
Canada	2902948
China	105073106
Cyprus	1120086
Denmark	2961399
European Patent Office	2961399